# Pathways of Resistance: Modern Multiple Myeloma Therapies and Overcoming Reliance on Genomic Integrity

## TL;DR

This paper reviews multiple myeloma therapies and explores new strategies to overcome resistance and prevent cancer relapse.

## Contribution

The paper introduces potential new therapeutic approaches using immunogenic cell death to prevent myeloma relapse.

## Key findings

- Multiple myeloma incidence has increased by 120% over three decades due to an aging population.
- Current therapies target weaknesses in the apoptotic mechanism of myeloma cells.
- Immunogenic cell death may offer a vaccine-like effect to prevent relapse in multiple myeloma.

## Abstract

Multiple myeloma (MM) is the second most common hematological malignancy in the US and Europe—comprising approximately 10% of all hematologic cancer cases—and its incidence has increased over the last three decades by approximately 120% due to an aging world population. It remains an incurable cancer among diseases in modern medicine. This review outlines the relevant cancer biology of MM, with a special emphasis on the role of tumor protein p53. We provide the most up-to-date summary of the current drugs in clinical or pre-clinical trials targeting weaknesses in the MM apoptotic mechanism. In addition, we highlight the potential for new routes to strike and kill myeloma cells, possibly creating a vaccine-like effect that prevents relapse, using the principles of immunogenic cell death (ICD).